{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T12:42:19Z","timestamp":1767703339598,"version":"build-2065373602"},"reference-count":63,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2003,4,1]],"date-time":"2003-04-01T00:00:00Z","timestamp":1049155200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2003,4,1]],"date-time":"2003-04-01T00:00:00Z","timestamp":1049155200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Psychoneuroendocrinology"],"published-print":{"date-parts":[[2003,4]]},"DOI":"10.1016\/s0306-4530(02)00129-4","type":"journal-article","created":{"date-parts":[[2003,3,25]],"date-time":"2003-03-25T19:21:05Z","timestamp":1048620065000},"page":"97-108","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":82,"special_numbering":"S2","title":["Hyperprolactinemia and bone mineral density: the potential impact of antipsychotic agents"],"prefix":"10.1016","volume":"28","author":[{"given":"U.","family":"Naidoo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.C.","family":"Goff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Klibanski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/S0306-4530(02)00129-4_BIB1","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/0006-3223(95)00062-L","article-title":"Osteoporosis and schizophrenia: can we limit known risk factors?","volume":"38","author":"Abraham","year":"1995","journal-title":"Biological Psychiatry"},{"issue":"5","key":"10.1016\/S0306-4530(02)00129-4_BIB2","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/0006-3223(96)82517-0","article-title":"Osteoporosis demonstrated by dual energy X-ray absorptiometry in chronic schizophrenic patients","volume":"40","author":"Abraham","year":"1996","journal-title":"Biological Psychiatry"},{"key":"10.1016\/S0306-4530(02)00129-4_BIB3","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/S0006-3223(97)00190-X","article-title":"Multiple fixed doses of \u2018Seroquel\u2019 (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo","volume":"42","author":"Arvanitis","year":"1997","journal-title":"Biological Psychiatry"},{"issue":"1","key":"10.1016\/S0306-4530(02)00129-4_BIB4","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1159\/000117734","article-title":"Calcium metabolism in schizophrenic patients on long-term neuroleptic therapy","volume":"6","author":"Baastrup","year":"1980","journal-title":"Neuropsychobiology"},{"issue":"6","key":"10.1016\/S0306-4530(02)00129-4_BIB5","first-page":"996","article-title":"Osteopenia in women with hypothalamic amenorrhea: a prospective study","volume":"78","author":"Biller","year":"1991","journal-title":"Obstetrics and Gynecology"},{"issue":"4","key":"10.1016\/S0306-4530(02)00129-4_BIB6","first-page":"333","article-title":"Molecular basis and clinical application of biological markers of bone turnover","volume":"17","author":"Calvo","year":"1996","journal-title":"Endocrine Reviews"},{"key":"10.1016\/S0306-4530(02)00129-4_BIB7","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1001\/jama.1984.03340290040017","article-title":"Decreased spinal mineral content in amenorrheic women","volume":"251","author":"Cann","year":"1984","journal-title":"Journal of the American Medical Association"},{"issue":"4","key":"10.1016\/S0306-4530(02)00129-4_BIB8","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1016\/S0031-3955(16)39018-6","article-title":"Osteoporosis as a pediatric problem","volume":"42","author":"Carrie-Fassler","year":"1995","journal-title":"Pediatric Clinics of North America"},{"key":"10.1016\/S0306-4530(02)00129-4_BIB9","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.1172\/JCI112234","article-title":"Estimation of bone turnover evaluated by 47Ca-kinetics","volume":"76","author":"Charles","year":"1985","journal-title":"Journal of Clinical Investigation"},{"key":"10.1016\/S0306-4530(02)00129-4_BIB10","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/BF01880414","article-title":"Screening procedures for women at risk for postmenopausal osteoporosis","volume":"1","author":"Christiansen","year":"1990","journal-title":"Osteoporosis International"},{"issue":"6","key":"10.1016\/S0306-4530(02)00129-4_BIB11","doi-asserted-by":"crossref","first-page":"E1216","DOI":"10.1152\/ajpendo.2000.279.6.E1216","article-title":"Effects of prolactin on osteoblast alkaline phosphatase and bone formation in the developing rat","volume":"279","author":"Coss","year":"2000","journal-title":"American Journal of Physiology. Endocrinology and Metabolism"},{"key":"10.1016\/S0306-4530(02)00129-4_BIB12","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S0920-9964(97)00036-4","article-title":"The acute and long-term effect of olanzapine compared with placebo and haloperidol on serum prolactin concentrations","volume":"26","author":"Crawford","year":"1997","journal-title":"Schizophrenia Research"},{"issue":"2A","key":"10.1016\/S0306-4530(02)00129-4_BIB13","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/S0002-9343(05)80041-5","article-title":"Bone mass measurements and risk of fracture in Caucasian women: a review of findings from prospective studies","volume":"98","author":"Cummings","year":"1995","journal-title":"The American Journal of Medicine"},{"key":"10.1016\/S0306-4530(02)00129-4_BIB14","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/0009-8981(87)90433-5","article-title":"Estimation of whole body bone resorption rate: a comparison of urinary total hydroxyproline excretion with two radioisotopic tracxer methods in osteoporosis","volume":"166","author":"Deacon","year":"1987","journal-title":"Clinical Chemistry Acta"},{"issue":"8","key":"10.1016\/S0306-4530(02)00129-4_BIB15","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/0006-3223(89)90119-4","article-title":"Osteopenia, pathological fractures, and increased urinary calcium excretion in schizophrenic patients with polydipsia","volume":"26","author":"Delva","year":"1989","journal-title":"Biological Psychiatry"},{"key":"10.1016\/S0306-4530(02)00129-4_BIB16","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/BF01623829","article-title":"Evaluation of bone turnover in type I osteoporosis using biochemical markers specific for both bone formation and bone resorption","volume":"3","author":"Eastell","year":"1993","journal-title":"Osteoporosis International"},{"key":"10.1016\/S0306-4530(02)00129-4_BIB17","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1097\/00005053-198208000-00004","article-title":"Sexual dysfunction and plasma prolactin levels in neuroleptic-treated schizophrenic outpatients","volume":"170","author":"Ghadirian","year":"1982","journal-title":"The Journal of Nervous and Mental Disease"},{"key":"10.1016\/S0306-4530(02)00129-4_BIB18","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1176\/ajp.149.9.1189","article-title":"Cigarette smoking in schizophrenia: relationship to psychopathology and medication side effects","volume":"149","author":"Goff","year":"1992","journal-title":"American Journal of Psychiatry"},{"key":"10.1016\/S0306-4530(02)00129-4_BIB19","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1097\/00004714-199808000-00009","article-title":"An exploratory haloperidol-controlled dose-finding study of ziprasidone in hospitalized patients with schizophrenia or schizoaffective disorder","volume":"18","author":"Goff","year":"1998","journal-title":"Journal Clinical Psychopharmacology"},{"key":"10.1016\/S0306-4530(02)00129-4_BIB20","doi-asserted-by":"crossref","first-page":"777","DOI":"10.7326\/0003-4819-104-6-777","article-title":"Osteoporosis in men with hyperprolactinemic hypogonadism","volume":"104","author":"Greenspan","year":"1986","journal-title":"Annals of Internal Medicine"},{"key":"10.1016\/S0306-4530(02)00129-4_BIB21","doi-asserted-by":"crossref","first-page":"526","DOI":"10.7326\/0003-4819-110-7-526","article-title":"Importance of gonadal steroids to bone mass in men with hyperprolactinemic hypogonadism","volume":"110","author":"Greenspan","year":"1989","journal-title":"Annals of Internal Medicine"},{"issue":"10","key":"10.1016\/S0306-4530(02)00129-4_BIB22","doi-asserted-by":"crossref","first-page":"790","DOI":"10.7326\/0003-4819-133-10-200011210-00011","article-title":"Prevalence and predictive factors for regional osteopenia in women with anorexia nervosa","volume":"133","author":"Grinspoon","year":"2000","journal-title":"Annals of Internal Medicine"},{"key":"10.1016\/S0306-4530(02)00129-4_BIB23","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1001\/archpsyc.1978.01770340072008","article-title":"Relation of plasma prolactin to clinical response in schizophrenic patients","volume":"35","author":"Gruen","year":"1978","journal-title":"Archives of General Psychiatry"},{"key":"10.1016\/S0306-4530(02)00129-4_BIB24","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1001\/archpsyc.1978.01770250110011","article-title":"Prolactin responses to neuroleptics in normal and schizophrenics subjects","volume":"35","author":"Gruen","year":"1978","journal-title":"Archives of General Psychiatry"},{"issue":"5","key":"10.1016\/S0306-4530(02)00129-4_BIB25","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1097\/00006842-199509000-00011","article-title":"Decreased bone mineral density in medicated psychiatric patients","volume":"57","author":"Halbreich","year":"1995","journal-title":"Psychosomatic Medicine"},{"issue":"6","key":"10.1016\/S0306-4530(02)00129-4_BIB26","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1172\/JCI113523","article-title":"Age and bone mass as predictors of fracture in a prospective study","volume":"81","author":"Hui","year":"1988","journal-title":"Journal of Clinical Investigation"},{"key":"10.1016\/S0306-4530(02)00129-4_BIB27","first-page":"95","article-title":"Tolerance to prolactin secretion in the long-term treatment with neuroleptics in schizophrenia","volume":"40","author":"Igarashi","year":"1985","journal-title":"Advances in Biochemistry and Psychopharmacology"},{"key":"10.1016\/S0306-4530(02)00129-4_BIB28","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1001\/archpsyc.1988.01800330013001","article-title":"Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine","volume":"45","author":"Kane","year":"1988","journal-title":"Archives of General Psychiatry"},{"issue":"156","key":"10.1016\/S0306-4530(02)00129-4_BIB29","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1176\/ajp.156.2.286","article-title":"Clinical and theoretical implications of 5HT2 and D2 occupancy of clozapine, risperidone and olanzapine in schizophrenia","volume":"1999","author":"Kapur","year":"1999","journal-title":"American Journal of Psychiatry"},{"key":"10.1016\/S0306-4530(02)00129-4_BIB30","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1176\/ajp.144.10.1335","article-title":"Abnormal prolactin response to haloperidol challenge in men with schizophrenia","volume":"144","author":"Keks","year":"1987","journal-title":"American Journal of Psychiatry"},{"key":"10.1016\/S0306-4530(02)00129-4_BIB31","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1097\/00004714-199902000-00011","article-title":"Prolactin levels and adverse events in patients treated with risperidone","volume":"19","author":"Kleinberg","year":"1999","journal-title":"Journal of Clinical Psychopharmacology"},{"key":"10.1016\/S0306-4530(02)00129-4_BIB32","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1056\/NEJM198012253032605","article-title":"Decreased bone density in hyperprolactinemic women","volume":"303","author":"Klibanski","year":"1980","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/S0306-4530(02)00129-4_BIB33","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1192\/bjp.139.5.400","article-title":"Neuroendocrine tests during treatment with neuroleptic drugs: I. Plasma prolactin response to haloperidol challenge","volume":"139","author":"Kolakowski","year":"1981","journal-title":"British Journal of Psychiatry"},{"key":"10.1016\/S0306-4530(02)00129-4_BIB34","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1210\/jcem-59-6-1050","article-title":"Vertebral body bone mineral content in hyperprolactinemic women","volume":"59","author":"Koppelman","year":"1984","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"10.1016\/S0306-4530(02)00129-4_BIB35","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1176\/ajp.136.1.108","article-title":"Serum prolactin and clinical state during neuroleptic treatment and withdrawal","volume":"136","author":"Laughren","year":"1979","journal-title":"American Journal of Psychiatry"},{"issue":"6","key":"10.1016\/S0306-4530(02)00129-4_BIB36","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1016\/0002-9378(92)91400-5","article-title":"The effect of sex steroids on the skeleton in premenopausal women","volume":"166","author":"Lindsay","year":"1992","journal-title":"American Journal of Obstetrics and Gynecology"},{"key":"10.1016\/S0306-4530(02)00129-4_BIB37","series-title":"Harrison\u2019s Principles of Internal Medicine","article-title":"Osteoporosis","author":"Lindsay","year":"2001"},{"issue":"6","key":"10.1016\/S0306-4530(02)00129-4_BIB38","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1210\/jcem.84.6.5710","article-title":"Bone densitometry: the best way to detect osteoporosis and to monitor therapy","volume":"84","author":"Miller","year":"1999","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"10.1016\/S0306-4530(02)00129-4_BIB39","first-page":"271","article-title":"Determination of galactosyl hydroxylysine in urine as a means for the identification of osteoporotic women","volume":"3","author":"Moro","year":"1988","journal-title":"Bone and Mineral"},{"key":"10.1016\/S0306-4530(02)00129-4_BIB40","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/BF02556339","article-title":"Urinary \u03b2-1-galactosyl-o-hyrdoxylysine (GH) as a marker of collagen turnover of bone","volume":"42","author":"Moro","year":"1988","journal-title":"Calcified Tissue International"},{"key":"10.1016\/S0306-4530(02)00129-4_BIB41","unstructured":"National Institutes of Health, 2000. Osteoporosis and Related Bone Diseases, National Resource Center, Osteoporosis Overview."},{"key":"10.1016\/S0306-4530(02)00129-4_BIB42","doi-asserted-by":"crossref","unstructured":"NIH Consensus Conference Development Panel on Osteoporosis Prevention, Diagnosis and Therapy, 2001. Journal of the American Medical Association 285(6), 785\u2013795 (Consensus Conference: From the National Institutes of Health).","DOI":"10.1001\/jama.285.6.785"},{"issue":"19","key":"10.1016\/S0306-4530(02)00129-4_BIB43","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1056\/NEJM200105103441904","article-title":"Effect of parathyroid hormone (1\u201334) on fractures and bone mineral density in postmenopausal women with osteoporosis","volume":"344","author":"Neer","year":"2001","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/S0306-4530(02)00129-4_BIB44","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1159\/000402339","article-title":"Neuroleptic drugs and sexual function in schizophrenics","volume":"15","author":"Nestores","year":"1980","journal-title":"Modern Problems in Pharmacopsychiatry"},{"issue":"11","key":"10.1016\/S0306-4530(02)00129-4_BIB45","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1001\/archinte.1981.00340120079016","article-title":"Postabsorptive urinary hydroxyproline test in patients with metastatic bone disease from breast cancer","volume":"141","author":"Niell","year":"1981","journal-title":"Archives of Internal Medicine"},{"key":"10.1016\/S0306-4530(02)00129-4_BIB46","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1007\/BF00310161","article-title":"Estimation of the effect of salmon calcitonin in established osteoporosis by biochemical bone markers","volume":"55","author":"Nielsen","year":"1994","journal-title":"Calcified Tissue International"},{"key":"10.1016\/S0306-4530(02)00129-4_BIB47","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1097\/00004714-199808000-00010","article-title":"Plasma prolactin and central D2 receptor occupancy in antipsychotic drug-treated patients","volume":"18","author":"Nordstrom","year":"1998","journal-title":"Journal of Clinical Psychopharmacology"},{"issue":"Suppl.","key":"10.1016\/S0306-4530(02)00129-4_BIB48","doi-asserted-by":"crossref","first-page":"S67","DOI":"10.1016\/S0920-9964(98)00158-3","article-title":"Prolactin and antipsychotic medications: mechanism of action","volume":"35","author":"Petty","year":"1999","journal-title":"Schizophrenia Research"},{"key":"10.1016\/S0306-4530(02)00129-4_BIB49","first-page":"103","article-title":"Galactorrhea and neuroleptics","volume":"38","author":"Plante","year":"1967","journal-title":"Laval Medical"},{"key":"10.1016\/S0306-4530(02)00129-4_BIB50","doi-asserted-by":"crossref","first-page":"459","DOI":"10.3109\/00365518609083698","article-title":"Hydroxyproline\/creatinine ratios as estimates of bone resorption in early postmenopausal women. Fasting and 24-hour urine samples compared","volume":"46","author":"Podenphant","year":"1986","journal-title":"Scandinavian Journal of Clinical Laboratory Investigation"},{"key":"10.1016\/S0306-4530(02)00129-4_BIB51","doi-asserted-by":"crossref","first-page":"287","DOI":"10.3109\/10408369109106867","article-title":"Osteocalcin: diagnostic methods and clinical applications","volume":"28","author":"Power","year":"1991","journal-title":"Critical Reviews in Clinincal Laboratory Sciences"},{"key":"10.1016\/S0306-4530(02)00129-4_BIB52","doi-asserted-by":"crossref","first-page":"239","DOI":"10.5694\/j.1326-5377.1957.tb57868.x","article-title":"Breast changes in the male and female with chlorpromazine or reserpine therapy","volume":"44","author":"Robinson","year":"1957","journal-title":"Medical Journal of Australia"},{"year":"1987","series-title":"Prolactin and Schizophrenia in Psychopharmacology: The Third Generation of Progress","author":"Rubin","key":"10.1016\/S0306-4530(02)00129-4_BIB53"},{"key":"10.1016\/S0306-4530(02)00129-4_BIB54","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1192\/bjp.106.443.732","article-title":"Clinical trials with Mellaril in the treatment of schizophrenia","volume":"106","author":"Sandison","year":"1960","journal-title":"Journal of Mental Science"},{"issue":"2","key":"10.1016\/S0306-4530(02)00129-4_BIB55","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/S0950-351X(95)80386-6","article-title":"Clinical Impact of hyperprolactinemia","volume":"9","author":"Schlechte","year":"1995","journal-title":"Baillieres Clinical Endocrinology and Metabolism"},{"key":"10.1016\/S0306-4530(02)00129-4_BIB56","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1210\/jcem-64-5-1021","article-title":"Forearm and vertebral bone mineral in treated and untreated hyperprolactinemic amenorrhea","volume":"64","author":"Schlechte","year":"1987","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"issue":"2A","key":"10.1016\/S0306-4530(02)00129-4_BIB57","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/S0002-9343(97)90029-2","article-title":"Osteoporosis: trials and tribulations","volume":"103","author":"Seeman","year":"1997","journal-title":"American Journal of Medicine"},{"key":"10.1016\/S0306-4530(02)00129-4_BIB58","first-page":"1238","article-title":"Sexual side effects of antipsychotic medication: evaluation and interventions","volume":"41","author":"Sullivan","year":"1990","journal-title":"Hospital and Community Psychiatry"},{"key":"10.1016\/S0306-4530(02)00129-4_BIB59","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1176\/ajp.154.4.457","article-title":"Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial","volume":"154","author":"Tollefson","year":"1997","journal-title":"American Journal of Psychiatry"},{"key":"10.1016\/S0306-4530(02)00129-4_BIB60","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1097\/00004714-199710000-00010","article-title":"Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders","volume":"17","author":"Tran","year":"1997","journal-title":"Journal of Clinical Psychopharmacology"},{"key":"10.1016\/S0306-4530(02)00129-4_BIB61","doi-asserted-by":"crossref","first-page":"197","DOI":"10.3109\/10408369409084677","article-title":"Interpretation and clinical significance of alkaline phosphatase isoenzyme patterns","volume":"31","author":"Van Hoof","year":"1994","journal-title":"Critical Reviews in Clinical Laboratory Sciences"},{"key":"10.1016\/S0306-4530(02)00129-4_BIB62","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1159\/000119265","article-title":"Galactorrhea and hyperprolactinemia in schizophrenic patients on neuroleptics: frequency and etiology","volume":"33","author":"Windgassen","year":"1996","journal-title":"Neuropsychobiology"},{"key":"10.1016\/S0306-4530(02)00129-4_BIB63","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1248\/bpb.17.836","article-title":"Urinary excretion levels of hydroxylysine glycosides in osteoporotic patients","volume":"17","author":"Yoshihara","year":"1994","journal-title":"Biological Pharmaceutical Bulletin"}],"container-title":["Psychoneuroendocrinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0306453002001294?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0306453002001294?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,5]],"date-time":"2025-10-05T16:24:42Z","timestamp":1759681482000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0306453002001294"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,4]]},"references-count":63,"alternative-id":["S0306453002001294"],"URL":"https:\/\/doi.org\/10.1016\/s0306-4530(02)00129-4","relation":{},"ISSN":["0306-4530"],"issn-type":[{"type":"print","value":"0306-4530"}],"subject":[],"published":{"date-parts":[[2003,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hyperprolactinemia and bone mineral density: the potential impact of antipsychotic agents","name":"articletitle","label":"Article Title"},{"value":"Psychoneuroendocrinology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/S0306-4530(02)00129-4","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"converted-article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2003 Elsevier Science Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}